☆ 3.8 Editorial Material

First-line therapy in advanced Renal Cell Carcinoma A randomized, open-label Phase-III-Study Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib compared to Sunitinib Monotherapy as First-Line Treatment for locally advanced or metastatic Renal Cell Carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO

UROLOGE (2017)

Get Full Text
Add to Collection

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.